Learn More
Early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) significantly enhance survival of severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis: results of the CAMELIA clinical trial Background Tuberculosis (TB) remains the largest cause of death among people living with HIV/AIDS, especially(More)
BACKGROUND Shortening the interval between antituberculosis treatment onset and initiation of antiretroviral therapy (ART) reduces mortality in severely immunocompromised human immunodeficiency virus (HIV)-infected patients with tuberculosis. A better understanding of causes and determinants of death may lead to new strategies to further enhance survival.(More)
Background This study aims to evaluate the reconstitution of NK cell functions in HIV/TB co-infected patients developing IRIS versus those not having IRIS after TB and anti-retroviral treatment initiation. Methods (i) 138 HIV+/TB+ patients enrolled in the CAMELIA trial (ANRS 1295-CIPRA/KH001-DAIDS-ES ID10425) in Cambodia and 36 HIV+ patients with CD4 + T(More)
OBJECTIVE To investigate the impact of tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) upon immunological recovery and the T-cell compartment after initiation of TB and antiretroviral therapy (ART). DESIGN AND METHODS We prospectively evaluated T-cell immunophenotypes by flow cytometry and cytokines by Luminex assays in a(More)
  • 1